Circulating angiogenic cells and Alzheimer's disease: contribution of the bone marrow to the pathogenesis of the disease.

M. Sadowski

DOI: https://doi.org/10.3233/JAD-2010-01343

Abstract:The most prevailing view on the pathogenesis of sporadic Alzheimer’s disease (AD) assumes that chronic imbalance between production and clearance of amyloid-β (Aβ) leads to accumulation of this hydrophobic and aggregation prone peptide in the brain and induces a neurodegenerative cascade [1]. Removal of Aβ through the blood-brain-barrier (BBB) to the bloodstream constitutes one of the critical pathways of Aβ clearance from the brain. Connected by tight junctions, endothelial cells line the cerebral vasculature and constitute the luminal layer of the BBB. Such endothelial cells are directly responsible for the active transport of numerous blood-borne elements to the brain and express the low density lipoprotein receptor-related protein 1 (LRP-1) which serves as a major Aβ clearance receptor. Numerous data indicate damage and dysfunction of the endothelial cell layer in AD patients and in AD transgenic animals, which undoubtedly contributes to the dysfunction of the BBB and impairment of its protective Aβ clearance capacity [2]. This dysfunction is exacerbated by Aβ itself, which shows pronounced vasculotropism and vasculotoxicity. Virtually all AD cases have some extent of cerebral amyloid angiopathy. Aβ peptide was shown to inhibit angiogenesis [3] and to be directly toxic to brain endothelial cells [4]. In this issue of the Journal of Alzheimer’s Disease, Dr. Soon-Tae Lee and colleagues described dysfunction of circulating angiogenic cells (CACs) in patients with sporadic AD [5]. Recently, the same group also reported a reduced number of CACs in AD patients [6], which inversely correlated with severity of the disease on cross-sectional study. These original observations contribute to our understanding of the etiopathogenesis of the vasculopathy and BBB dysfunction associated with AD.